Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of
BMS-936558 in combination with or without a peptide vaccine.
The purpose of this study is to test the side effects of an investigational vaccine with an
immune booster. Investigators also wish to find out its effects on the patient's immune
system and whether it will shrink their melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Bristol-Myers Squibb Medarex National Cancer Institute (NCI)